

1  
--Claim 128. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO: 11, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

2  
Claim 129. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO: 48, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

3  
Claim 130. The antibody of claim 128 further comprising a VH domain having an amino acid sequence of SEQ ID NO: 48.

4  
Claim 131. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH complementarity determining region (CDR) 1 having an amino acid sequence of SEQ ID NO: 10, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

5  
Claim 132. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO: 19, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim <sup>6</sup>~~133~~. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO: 20, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

Claim <sup>7</sup>~~134~~. A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO: 39, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.--

<sup>8</sup>~~137~~. (New) The method of claim <sup>4</sup>~~131~~, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

<sup>9</sup>~~138~~. (New) The method of claim <sup>4</sup>~~131~~, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

<sup>10</sup>~~139~~. (New) The method of claim <sup>4</sup>~~131~~, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

<sup>11</sup>~~140~~. (New) The method of claim <sup>5</sup>~~132~~, wherein the antibody further comprises a VL CDR 1 having an amino acid sequence of SEQ ID NO:39.

<sup>12</sup>~~141~~. (New) The method of claim <sup>5</sup>~~132~~, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

<sup>13</sup>~~142~~. (New) The method of claim <sup>5</sup>~~132~~, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

<sup>14</sup>~~143~~. (New) The method of claim <sup>6</sup>~~133~~, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

<sup>15</sup>~~144~~. (New) The method of claim <sup>6</sup>~~133~~, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

<sup>16</sup>~~145~~. (New) The method of claim <sup>6</sup>~~133~~, wherein the antibody further comprises a VL CDR3, having an amino acid sequence of SEQ ID NO:6.

17  
146. (New) The method of claim 131, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

18  
147. (New) The method of claim 131, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

19  
148. (New) The method of claim 132, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

20  
149. (New) The method of claim 146, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

21  
150. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

22  
151. (New) The method of claim 146, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

23  
152. (New) The method of claim 146, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

24  
153. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

25  
154. (New) The method of claim 147, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

26  
155. (New) The method of claim 147, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

27  
156. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

28  
157. (New) The method of claim 148, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

29  
158. (New) The method of claim 148, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

30  
159. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.

<sup>31</sup>  
160. (New) The method of claim <sup>20</sup>149, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

<sup>32</sup>  
161. (New) The method of claim <sup>20</sup>149, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

<sup>33</sup>  
162. (New) The method of claim <sup>7</sup>134, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

<sup>34</sup>  
--Claim <sup>7</sup>163. The method of claim <sup>7</sup>134, wherein the antibody further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.--

<sup>35</sup>  
165. (New) The method of claim <sup>33</sup>162, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

<sup>36</sup>  
166. (New) The method of claim <sup>33</sup>162, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

<sup>37</sup>  
167. (New) The method of claim <sup>33</sup>162, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

<sup>38</sup>  
168. (New) The method of claim <sup>33</sup>162, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

<sup>39</sup>  
169. (New) The method of claim <sup>34</sup>163, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

<sup>40</sup>  
170. (New) The method of claim <sup>34</sup>163, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

<sup>41</sup>  
171. (New) The method of claim <sup>34</sup>163, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

42  
--Claim 172. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5, a VLCDR3 having an amino acid sequence of SEQ ID NO: 6, and a VH CDR1 having an amino acid sequence of SEQ ID NO: 10, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

43  
Claim 173. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5, a VLCDR3 having an amino acid sequence of SEQ ID NO: 6, and a VH CDR2 having an amino acid sequence of SEQ ID NO: 19, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.

44  
Claim 174. A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5, a VLCDR3 having an amino acid sequence of SEQ ID NO: 6, and a VH CDR3 having an amino acid sequence of SEQ ID NO: 20, wherein the antibody immunospecifically binds to a RSV F antigen and the effective amount of the antibody results in an effective neutralizing titer of an antibody.--

45 35  
175. (New) The method of claim 165, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

46 35  
176. (New) The method of claim 165, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

47 35  
177. (New) The method of claim 165, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

48 17  
178. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

49 17  
179. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

50 17  
180. (New) The method of claim 146, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

51 17  
181. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

52 18  
182. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

53 18  
183. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

54 18  
184. (New) The method of claim 147, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

55 185. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

56 186. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

57 187. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

58 188. (New) The method of claim 148, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

59 189. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

60 190. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

61 191. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

62 192. (New) The method of claim 149, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

63 193. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

64

1 2 3 4-7

194. (New) The method of any one of claims ~~128~~, ~~129~~, ~~130~~ or ~~131-134~~, wherein the effective amount is 15 mg/kg or less, 10 mg/kg or less, 5 mg/kg or less or 3 mg/kg or less or 1.5 mg/kg or less.

65

1 2 3 4-7

195. (New) The method of any one of claims ~~128~~, ~~129~~, ~~130~~ or ~~131-134~~, wherein the effective neutralizing titer is at least 1  $\mu\text{g/ml}$ , at least 2  $\mu\text{g/ml}$ , at least 4  $\mu\text{g/ml}$ , at least 6  $\mu\text{g/ml}$ , at least 30  $\mu\text{g/ml}$ , 35  $\mu\text{g/ml}$ , at least 40  $\mu\text{g/ml}$ , at least 50  $\mu\text{g/ml}$ , at least 75  $\mu\text{g/ml}$ , at least 100  $\mu\text{g/ml}$ , at least 150  $\mu\text{g/ml}$  or at least 200  $\mu\text{g/ml}$ .

66

1 2 3 4-7

196. (New) The method of any one of claims ~~128~~, ~~129~~, ~~130~~ or ~~131-134~~, wherein the effective neutralizing titer is maintained for at least 20 days, at least 25 days or at least 30 days after administration of the dose.

67

1 2 3 4-7

197. (New) The method of any one of claims ~~128~~, ~~129~~, ~~130~~ or ~~131-134~~, wherein the antibody is administered by a nebulizer or inhaler.

68

1 2 3 4-7

198. (New) The method of any one of claims ~~128~~, ~~129~~, ~~130~~ or ~~131-134~~, wherein the antibody is administered intramuscularly, intravenously or subcutaneously.

69

1 2 3 4-7

199. (New) The method of any one of claims ~~128~~, ~~129~~, ~~130~~ or ~~131-134~~, wherein the antibody is a monoclonal antibody, a human antibody, a humanized antibody, a multispecific antibody, a chimeric antibody, a Fab fragment, a single-chain Fv or a single chain antibody.

70

1 2 3 4-7

200. (New) The method of any one of claims ~~128~~, ~~129~~, ~~130~~ or ~~131-134~~, wherein the antibody is administered 1, 2, 3, 4 or 5 times during the RSV season.

71

1 2 3 4-7

201. (New) The method of any one of claims ~~128~~, ~~129~~, ~~130~~ or ~~131-134~~, wherein the mammal is a human subject.

72

71

202. (New) The method of claim ~~201~~, wherein the human subject is a human infant, a human infant born prematurely or at risk of hospitalization for a RSV infection, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

73

1 2 3 4-7

203. (New) The method of any one of claims ~~128~~, ~~129~~, ~~130~~ or ~~131-134~~ further comprising administering to the mammal hormonal therapy, immunotherapy or an anti-inflammatory agent.